Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.
9monon MSN
and interest in Recursion’s data and technology solutions,” said Chris Gibson, co-founder and CEO of Recursion. “It is great ...
For building a pharma company that uses AI plus tiny snapshots to find treatments that humans would miss, Chris Gibson is one of Fast Company's Most Creative People in Business. These are the four ...
Recursion was able to use its artificial intelligence ... but I think for the techbio industry as well," said CEO and ...
Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announces that co-founder and CEO Chris Gibson, PhD will present at the ...
Salt Lake City, UT, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announces that co-founder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results